Metabolize Closes $3.2 Million Seed Round Led by Astanor to Fund NATLEAN Launch

Metabolize has completed a $3.2 million seed financing led by Astanor, with participation from Maia Ventures, LongGame Venture and SOSV, the company said on October 15, 2026. The financing was announced by PR Newswire.

Metabolize's Seed Round and NATLEAN Plans

Metabolize is a science-first consumer health company built on Stanford Medicine-originated research. The investment will accelerate commercialization of its Precision Metabolite™ Technology and support continued investment in the development, validation and manufacturing of its metabolic health products, the company said.

Founded in 2024 by Dr. Morris Laster and Gideon Meir, Metabolize develops Precision Metabolite™ Technology based on naturally occurring compounds with defined biological roles identified through research led by Jonathan Long, PhD, associate professor of pathology at Stanford Medicine. Through an exclusive license to Stanford-originated intellectual property, the company is translating these patent-protected discoveries into a portfolio of consumer metabolic health products.

"GLP-1 therapies have fundamentally changed the landscape of weight management and metabolic health, but they haven't solved every challenge," said Dr. Morris Laster, founder and CEO of Metabolize. "We founded Metabolize to translate groundbreaking research into innovative consumer products that address these unmet needs and ultimately help people live healthier lives."

Metabolize's first consumer product, NATLEAN, is expected to launch in January 2027. It is designed to support individuals transitioning off GLP-1 therapies by helping reduce food noise, support healthy appetite regulation and promote long-term weight management. NATLEAN represents the company's first commercial application of Precision Metabolite™ Technology, with additional products in development across its broader metabolic health portfolio.

"What stood out to us about Metabolize was the strength of the original research, the team's thoughtful approach to translating that science into consumer products, and their vision for building a new category in metabolic health," said Christina Ulardic, Partner at Astanor.

Metabolize's Funding and Product Records

According to akta.pro company records, Metabolize raised a funding round in August 2025 led by SOSV (SOSV SF & NY, fka IndieBio), marking the company's first institutional backing, with the amount not disclosed. The same records list one funding round on file, a 2025-08 seed led by SOSV.

The records also show that in 2024 Metabolize opened a pre-launch waitlist for NatLean, a precision metabolite supplement targeting post-GLP-1 satiety support, with the product still preparing for commercial launch. In 2024 the company selected Shopify as the e-commerce platform to power direct-to-consumer sales, transactions and personalized advertising for the NatLean launch.

NATLEAN's January 2027 Launch

Metabolize expects NATLEAN to launch in January 2027, the company said. The product is designed to support individuals transitioning off GLP-1 therapies, and additional products remain in development across its broader metabolic health portfolio.